Addex Therapeutics announced encouraging preclinical data showing its GABAB PAM candidate demonstrated robust antitussive efficacy and improved lung pathology in a bleomycin-induced IPF chronic cough model.
Key takeaways
GABAB PAM candidate showed significant reductions in cough frequency and increased cough latency with chronic QD administration in BLM-exposed animals.
Improved lung pathology with lower Ashcroft scores and reduced affected lung tissue at Day 7 and Day 28 vs. untreated controls.
Favorable safety profile with no changes in respiratory rate or body temperature; well-tolerated for chronic use.
Supports potential as novel, well-tolerated treatment for chronic cough in IPF patients.
Prior non-human primate studies also showed robust efficacy with stable safety.